Preliminary Final Report

• Revenues up 19.2% to $7.63 million
• Loss down 47.7% to $7.92 million
• Successful capital raisings of $20 million

Syntara Limited, a clinical-stage drug development company, has reported its preliminary final results for the year ended 30 June 2025. The company saw a 19.2% increase in revenues to $7.63 million, while its loss from ordinary activities after tax attributable to the owners of Syntara Limited was down 47.7% to $7.92 million. Syntara is focused on the development of its pipeline, primarily its lead candidate amsulostat (SNT-5505) for the treatment of myelofibrosis, a bone marrow cancer. During the year, amsulostat was granted Fast Track Designation by the FDA, having already achieved Orphan Drug Designation. The company also has other drug candidates targeting fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. Syntara completed successful capital raisings during the year, securing $5 million in July 2024 and $15 million in December 2024 through institutional placements. The funds will be used to support the company's drug development activities. The company also announced the appointment of a new Company Secretary, Mr. Cameron Billingsley, in February 2025.